| abstract |
This disclosure relates, in part, to methods for treating, preventing or reducing the rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). method. In certain aspects, the present disclosure provides ActRIIB antagonists for use in treating, preventing or reducing the rate of progression and/or severity of one or more complications (eg, anemia) associated with Janus kinase inhibitor therapy in a patient sex. |